| 丁春梅1 胡承平1,2 熊翔凤1 刘荣辉1 秦勇2.不同剂量糖皮质激素治疗老年哮喘急性发作的对比研究[J].现代生物医学进展英文版,2012,12(18):3529-3531. |
| 不同剂量糖皮质激素治疗老年哮喘急性发作的对比研究 |
| Comparative of Different Doses of Corticosteroids in Elderly Asthma AcuteAttack Patients |
| |
| DOI： |
| 中文关键词: 哮喘急性发作 老年 布地奈德 剂量 |
| 英文关键词: Asthma acute attack Elderly Budesonide Dose |
| 基金项目: |
|
| Hits: 835 |
| Download times: 1121 |
| 中文摘要: |
| 目的：探讨不同剂量吸入型糖皮质激素（ICS）治疗老年哮喘急性发作的疗效及安全性分析。方法：将108 例老年哮喘急性发
作患者随机分为A 组（34 例）、B 组（38 例）和C 组（36 例），分别吸入布地奈德200 μg/d、400 μg/d、800 μg/d；治疗3 个月后再随机
分为低剂量组（200μg/d，n=）和高剂量组（400μg/d）进行维持治疗，并随访观察12 个月。结果：治疗3 个月后，三组的临床症状评
分、肺功能较治疗前均有显著改善，差异有统计学意义（P<0.05）；B 组、C 组治疗后的临床症状评分、肺功能及症状消失时间均显
著优于A 组，而B 组、C 组之间差异无统计学意义（P>0.05）；A 组和B 组不良反应的发生率分别为5.9%，10.5%，显著低于C 组
30.6%，差异有统计学意义（P<0.05）；维持治疗期间，低剂量组复发率为21.2%，高剂量组为20.4%，差异无统计学意义（P>0.05）。结
论：老年哮喘急性发作患者给予ICS 400 μg/d 治疗剂量及200 μg/d 维持剂量即可取得较好的治疗效果，可减少不良反应，提高患
者的耐受性。 |
| 英文摘要: |
| Objective: To explore the clinical effect and safety of different doses corticosteroids on the treatment of elderly
bronchial asthma acute attack patients. Methods: 108 patients with bronchial asthma acute attack were randomly divided into three
groups including A group (n=34), B group (n=38) and C group (n=36), which inhaled budesonide for 200 μg/d, 400 μg/d and 800 μg/d,
respectively. After 3 months treatment, the patients were divided randomly into two groups including low dose group (200 μg/d, n=54),
high dose group (400 μg/d, n=54), which inhaled 200 μg/d and 400 μg/d of maintenance doses budesonide, and all the cases were followed-
up for 12 month. Results: After treatment for 12 months, the symptoms scores, lung function were significantly different from
those before treatment. There was significantly difference between B group and A group in the symptoms scores, lung function and the
time of the symptoms disappeared (P<0.05). The situation was the same between C group and A group, and there was significant difference
between B group and C group (P>0.05). The rate of side effect in A group and B group were 5.9% and 10.5%, respectively, which
was significantly lower in A group than C group (P<0.05). During the maintenance treatment, the recurrence rate in low dose group and
high dose group was not statistically different (21.2% vs.20.4%). Conclusions: The treatment doses of 400μg/d and maintenance doses of
200μg/d for elderly bronchial asthma acute attack patients could be effective to reduce the side effect and improve patients' tolerance. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
